Showing results (121-130 of 887) with videos related to
Sort By:
Pageof 89
Hepatology (Baltimore, Md.)|July 22, 2010
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic diseaseElizabeth K Speliotes, Johannah L Butler, Cameron D Palmer, et al.STAR Protocols|October 18, 2025
Protocol for discovering genetic variants associated with ATAC-seq footprint-inferred transcription factor bindingMax F Dudek, Brandon M Wenz, Benjamin F Voight, et al.European Heart Journal. Cardiovascular Pharmacotherapy|September 22, 2022
RNA-targeted therapeutics in cardiovascular disease: the time is nowKonstantin A Krychtiuk, Daniel J Rader, Christopher B GrangerBiochemical Society Transactions|October 31, 2015
Tribbles-1: a novel regulator of hepatic lipid metabolism in humansRobert C Bauer, Batuhan O Yenilmez, Daniel J RaderEndocrinology|May 22, 2002
Perspective: cardiovascular disease in the postgenomic era--lessons learned and challenges aheadJonathan A Epstein, Daniel J Rader, Michael S ParmacekThe Journal of Biological Chemistry|June 29, 2010
Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertasesJun Liu, Huq Afroza, Daniel J Rader, et al.Clinical Lipidology|April 17, 2012
Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategiesSadik H Kassim, James M Wilson, Daniel J RaderCurrent Opinion in Lipidology|February 12, 2011
Functional validation of new pathways in lipoprotein metabolism identified by human geneticsRobert C Bauer, Ioannis M Stylianou, Daniel J RaderJournal of Clinical Lipidology|February 18, 2014
JCL roundtable: drug treatment of severe forms of familial hypercholesterolemiaW Virgil Brown, Daniel J Rader, Anne C GoldbergCurrent Cardiology Reports|September 20, 2012
Targeting high density lipoproteins in the prevention of cardiovascular disease?Daniel B Larach, Emil M deGoma, Daniel J RaderPageof 89